How To Be A Dynamic Model

Published Sep 17, 2012
Princeton, NJ – Every year, news broadcasts detail reports about communicable diseases in our country. How do disease-control organizations make decisions about how to effectively treat these diseases? Most likely, they analyze the options using dynamic models. “A dynamic model is needed when evaluating an intervention against an infectious disease that 1) has an impact on disease transmission in the target population, or 2) alters the frequency distribution of strains (e.g., genotypes or serotypes),” says Dr. Richard Pitman, PhD, lead author on the paper, “Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5 .” Best practices for designing dynamic transmission modeling studies are presented in this paper. This paper is one of the seven papers in the series on modeling study best practices and is jointly published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and Medical Decision Making, the official journal of the Society for Medical Decision Making (SMDM).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×